The collaboration outlines plans for multiple in vivo studies, designed to test opaganib as a potential medical countermeasure to treat phosgene i ...

A spinoff company has been formed to produce a hormone supplement that reduces lung damage, but researchers still need to ...

To schedule a meeting with Edesa during the conferences, please contact conference organizers or the company directly at [email protected].

AFTER a perfect record in this year’s championship, Ballygalget will be hoping that they can cap their season off in style ...

VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO, Oct. 18 ...

The duration of the buy-back programme: 15 February 2024 to 15 January 2025.

A Charlottesville startup is developing new drugs that target inflammation for people with acute lung injuries. It's received ...

FDA’s feedback supports the initiation of the Phase III trialAgitation-Aggression in Borderline Personality Disorder (BPD) acknowledged as a possible therapeutic indicationOryzon may use STAXI-2 Trait ...

Council & the 3rd New Investment Conference in 2024 was held in Shanghai from August 28 to 30, 2024. On the evening of August 28, the prestigious 2024 Global and China Awards for Growth, Innovation, ...

Safety Review Committee (SRC) approves single ascending dose 4mg cohort in Phase 1 trial of PMC-403, preparing for multiple ascendi ...

MiNK Therapeutics Inc (INKT) reports significant progress in reducing operating expenses and advancing clinical trials, despite ongoing financial hurdles.